TRT Nonvasiv Tissue Regeneration & Lithotripsy
www.trtllc.com
TRANSITIONS
A NEWSLETTER FOR EQUITY HOLDERS OF TRT
Vol. 24 | June 2011

INVITATION TO INVESTORS: TRT's current Private Offering was extended.

Any interested parties may contact John Warlick or Michael Rozmajzl at (877) 966-1315 or via email at jwarlick@trtllc.com or mrozmajzl@trtllc.com.

SoftWaves™ Beat Focused Shockwaves

During the 2011 congress of the International Society for Medical Shockwave Treatment (ISMST) in Kiel, Germany, data from a study by Dr. Raoul Saggini of Central University of Sports Medicine in Chieti, Italy was presented comparing 90 chronic wound patients treated with focused shockwave technology versus TRT's patented unfocused (SoftWave™) shockwave technology.

The SoftWave™ group experienced a 78% success rate compared to only a 56% success rate for the focused shockwave treatment group. Equally significant was the observation that "unfocused shockwaves were much better tolerated by the patients." Many patients in the focused shockwave group complained of pain during treatment.

This study is also part of a larger randomized controlled study of chronic wounds in Italy that will be completed this year in support of reimbursement. This pivotal work is another clear indicator of the advantages of TRT's patented SoftWave™ technology over competitors' focused technology.

TRT Management (L to R facing camera: Dr. Richard Thiele, Special Advisor; Dr. Wolfgang Schaden, Director of Scientific Research; John Warlick, CEO) with ISMST attendees

More Publications

TRT's device studies continue to yield peer-reviewed publications. "Evidence Supporting Extracorporeal Shock Wave Therapy for Acute and Chronic Soft Tissue Wounds" was accepted for publication and will appear in the July issue of ***Wounds***.

Also, a second article resulting from TRT's burn study was accepted for publication in ***Annals of Surgery***. The study showed that in a randomized Phase II trial a single application of unfocused shockwaves (SoftWaves™) to a superficial 2nd degree (IIa°) burn wound after debridement significantly accelerates re-epithelialization compared to standard of care.

Diabetes Treatment

As TRT continues to address health issues of national and global importance, our portfolio of intellectual property increases accordingly. Our latest Notice of Allowance from the US Patent & Trademark Office focuses on the problem of diabetes, which is on the rise in the US due to the increase of obesity.

Pancreas Regeneration Treatment for Diabetes using Extracorporeal Acoustic Shock Waves utilizes our soft focused technology to stimulate the pancreas of a diabetic to reduce inflammation and restore normal insulin production. This is an area of great interest in the US due to the rising levels of obesity, which drive up health care costs. We believe TRT's technology will be a highly valuable tool in treating this disease and reducing the associated health care costs.

To that end, we just completed our first pre-clinical rat model experiments for diabetes and anticipate the results within 90 days.

TRT now holds rights to 20 patents. USPTO examiners are also reviewing several other TRT applications, including our cardiac device. We are optimistic that these applications will be granted allowances in the near future.

TRT Nonvasiv Tissue Regeneration & Lithotripsy
www.trtllc.com
TRANSITIONS
A NEWSLETTER FOR EQUITY HOLDERS OF TRT

Around the World

ISMST

TRT participated in the 14th annual congress of the ISMST in Germany June 9-11. This is the largest worldwide meeting of medical specialists interested in extracorporeal shockwave therapy (ESWT).

Physicians from 30 countries in North and South America, Europe, and Asia, including the regions of India and the Middle East, assembled to discuss the latest medical research on ESWT. Topics included medical shockwave treatment for ***cardiac disease, pain, tendinopathies, bone disease and injuries, spasticity, arthritis and joint maladies, asthma, cellulite, and wound healing, as well as ESWT's ability to stimulate stem cells***.

TRT's technology figured prominently in the research, with numerous studies involving our DermaGold or CardioGold devices. Our technology was also featured in several articles in the ISMST newsletter such as "Influence of Shock-Wave-Treatment on Migration, Proliferation and Genetic Expression of Fibroblasts", which showed that our technology accomplished in ***only 300 pulses*** what it took the Wolf Piezoson 1,000 pulses to achieve!

Across the Nation

Erectile Dysfunction/Diabetes/Stem Cell Trials

The renowned ***University of California at San Francisco*** initiated 3 trials in partnership with TRT. The trial on erectile dysfunction was recently completed and the preliminary results will be received by early July. We look forward to bringing you progress of the diabetes and stem cell trials that were also initiated.

Additional Stem Cell Trial

TRT is conducting a trial with the prestigious ***Rood & Riddle Equine Hospital*** on the enhancement of in vitro stem cell growth using ESWT. Preliminary results show an incredible ***1,000% increase in stem cell proliferation*** on stem cells treated with unfocused shock waves (SoftWaves™). TRT was recently issued a patent on this application.

Ovarian Cancer Trial

TRT has reached an agreement with ***Sloan Kettering, the world's premier cancer treatment center***, to commence an animal study on ovarian cancer using our patented SoftWave™ technology. Sloan Kettering initiated the study at their own expense with TRT contributing a device and training for the study. The ovarian cell implanted rats were treated on June 24th.

American Urological Association (AUA)

TRT attended the AUA Annual Meeting in Washington, DC in mid-May. This Annual Meeting is the world's largest gathering of urology professionals with more than 10,0000 participants.

As always, TRT's state-of-the-art LithoGold® urology system was on display, and several device demonstrations were scheduled as a result of our involvement in the meeting.

International Kidney Stone Institute (IKSI)

TRT also took part in IKSI's Advanced Stone Workshop June 16-17 in Indianapolis. The workshop titled "State-of-the-Art in the Surgical/Medical Management of Urolithiasis" showcased TRT's LithoGold during an evening session for some of the nation's most prominent urologists. Several attendees subsequently scheduled on-site demonstrations.

Demo Trail

And speaking of demos, TRT has been hot on the demo trail this quarter, holding device demonstrations for facilities and physicians groups in Fargo, ND, Omaha, NE, New York City and Washington, DC. We anticipate sales to follow later this year.

Tissue Regeneration Technologies, LLC
130 Arnold Mill Park, Woodstock, GA 30188
Tel: (770) 966-1315
Tdd: (877) 966-1315
Fax: (770) 592-8910
Web: www.trtllc.com